Press Releases

Rho Federal Systems Division, Inc. Awarded Statistical and Data Coordinating Center Contract in BARDA Medical Countermeasures Clinical Studies Network

Rho Federal Systems Division, Inc. Awarded Statistical and Data Coordinating Center Contract in BARDA Medical Countermeasures Clinical Studies Network CRO will serve to standardize data collection, management, and analysis across BARDA-supported network studies. Research Triangle Park, NC – November 9, 2020 – Rho, a full-service contract research organization (CRO) that helps pharmaceutical and biotechnology companies bring their products to market through high-quality clinical research services, announces the Rho Federal Systems Division, Inc. (RhoFED) was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services to manage a Statistical and Data Coordinating Center (SDCC) for BARDA’s Medical Countermeasures Clinical Studies Network. Under the contract, RhoFED will be responsible for standardizing data collection, management, and analysis across BARDA-supported network studies.

Shimmer Research Receives CE Certification for its Verisense™ Inertial Measurement Unit (IMU) Sensor for Clinical Trials

Shimmer’s wearable sensor is now recognized as a medical device in Europe, capable of providing continuous, medical-grade measurements of a person’s activity.

SCORR Releases 2020 Report on Health Science Company Marketing Trends

SCORR Marketing, a global health science marketing and communications firm, has released its eighth annual survey report, Marketing Trends in Health Science Services Companies. The report is free and features data that health science executives and marketers can use to understand how companies are approaching marketing in the midst of the COVID-19 pandemic. The report provides valuable insights that can guide strategic planning, budgeting, and tactics in the year ahead.

GT Medical Technologies Announces First Patient Treated in Registry Trial of GammaTile Therapy for Brain Tumors

GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced the first patient has been enrolled into its registry trial of GammaTile®, a FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for newly diagnosed malignant and recurrent brain tumors. The study will evaluate the safety and effectiveness of GammaTile Therapy in a real-world setting in up to 50 brain tumor centers across the United States.

eClinical Solutions Empowers the Digital Health Revolution at elluminate Engage 2020 Conference

Annual event by eClinical goes virtual on November 18-19 to highlight digital transformation of life sciences

Isohelix and Precision Genetics Partner to Expand COVID-19 Testing Using Saliva Collection Technology

Isohelix announces its state-of-the-art GeneFiX™ Saliva RNA Collection Device is the technology of choice for COVID-19 testing by Precision Genetics. The high-performance, easy-to-use device marks the latest addition to Precision Genetics’ extensive portfolio of validated COVID-19 testing options submitted under the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).

Pioneering research detects Hormone-Upregulated lncRNA within the lymphocyte-specific protein tyrosine kinase (HULLK) discovered in Prostate Cancer

Pioneering research conducted by the University of Virginia in collaboration with APIS Assay Technologies has discovered Hormone-Upregulated lncRNA within lymphocyte-specific protein tyrosine kinase is detectable in non-invasive prostate cancer patient samples. The breakthrough data provides a potential new approach to address the unmet medical need of early diagnostics for prostate cancer, in combination with avoiding the invasive cancer tissue sample collection from a biopsy.

Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

Australian clinical-stage drug development company Noxopharm (ASX: NOX) is pleased to announce it has joined with Bristol Myers Squibb (NYSE: BMY) in an Australian pilot study investigating the ability of Noxopharm’s immunotherapy drug candidate, Veyonda®, to overcome resistance to Bristol Myers Squibb’s nivolumab (Opdivo®) in the treatment of cancer.

Pill Connect secures £0.5m to take electronic smart pill bottle that monitors patient adherence to commercial launch

Pill Connect, formerly known as Elucid mHealth, has completed a £510,000 funding round to complete development of the design, electronics and software for submission to the regulatory authorities in both Europe and the US and continue through to commercial launch.

BioIVT to Host Emerging Technologies in Diagnostics Symposium

Advances include a rapid vaccine analysis platform, companion diagnostic for solid tumors, and bioanalytical validation methods for biomarkers and companion diagnostics

Shimmer Solicits Clinical Research Community Input on Expanded Open Wearables Initiative (OWEAR) Vision

As OWEAR embarks on its second year, organizers see potential to expand its positive industry impact beyond the organization’s original mission

Protheragen Offers License Opportunities for Drug Development Programs

Protheragen, a company founded in Ronkonkoma, New York, 2009, announces to offer license opportunities for drug R&D companies.

AI & Medicine Announces Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling for Drug Discovery

On October 24, 2020, AI & Medicine, one of the forerunners in the AI-assisted medicine area, announces it now provides PK/PD modeling service to help scientists and researchers more efficiently screen drugs and thus accelerating the process of new drug development. The company is known as an expert in applying artificial intelligence into drug discovery, personalized healthcare and various other medical applications.

Alfa Chemistry Offers Fluorinated Building Blocks for Material, Medicinal, Agricultural, Organic Chemistry Research

The benefits of fluorochemistry to pharmaceutical applications are obvious and the past decades has seen increasing synthesis of fluorinated compounds in the preparation of new pharmaceuticals and agrochemicals. To better meet the growing needs of customers worldwide, the New York-based chemical supplier Alfa Chemistry announced to offer high-purity fluorinated building blocks for various application scenarios such as material, medicine, agriculture and organic chemistry.

Notable Labs Announces Partnership With All4Cure

Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, and All4Cure, which has built a real world data powered network of patients, clinicians and researchers to dramatically improve outcomes for millions of patients with cancer, today announced their partnership. Notable will leverage All4Cure’s network to enhance and expand its functional precision oncology platform.

Matexcel Released a Series of Collagen Products for Worldwide Researchers

 Flow Cytometry Analysis in Plants Now Available at Lifeasible

WCG Appoints Two New Independent Directors to its Board

Dr. Kavita Patel and Ms. Pascale Witz bring global healthcare policy and pharmaceutical executive experience to WCG

IntegrateRNA miRNA Services: Powerful Support for miRNA Basic Research, Biomarker Discovery and Preclinical Trials

Plant Extracts at Alfa Chemistry Serve as Materials for Cosmetics, Health Food, and Medical Care